Get the Stockscreener App
37.47
1.26%
-0.48
After Hours:
37.47
Artivion Inc stock is traded at $37.47, with a volume of 231.10K.
It is down -1.26% in the last 24 hours and up +2.97% over the past month.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
See More
Previous Close:
$37.95
Open:
$37.64
24h Volume:
231.10K
Relative Volume:
0.54
Market Cap:
$1.82B
Revenue:
$441.33M
Net Income/Loss:
$9.76M
P/E Ratio:
187.54
EPS:
0.1998
Net Cash Flow:
$839.00K
1W Performance:
+3.91%
1M Performance:
+2.97%
6M Performance:
-9.78%
1Y Performance:
+62.77%
1-Day Range:
$37.42
$38.25
1-Week Range:
$35.23
$39.14
52-Week Range:
$22.22
$48.25
Artivion Inc Stock (AORT) Company Profile
Name
Artivion Inc
Sector
Industry
Phone
(770) 419-3355
Address
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
37.47 | 1.84B | 441.33M | 9.76M | 839.00K | 0.1998 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-13-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-17-25 | Initiated | Canaccord Genuity | Buy |
| Oct-23-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-22 | Reiterated | Lake Street | Buy |
| Aug-08-22 | Initiated | Lake Street | Buy |
| Mar-03-22 | Initiated | Stifel | Buy |
View All
Artivion Inc Stock (AORT) Latest News
Assessing Artivion (AORT) Valuation After FDA Approval Of NEXUS Aortic Arch System - simplywall.st
Ladenburg Thalmann upgrades Artivion (AORT) - MSN
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 85 Tel - GuruFocus
Endospan’s FDA nod for Nexus brings acquisition by Artivion closer - BioWorld News
Growth Value: Is Artivion Inc a momentum stock2026 Growth vs Value & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Artivion Receives FDA Clearance for NEXUS Aortic Arch System - Bitget
Artivion Secures FDA Approval for NEXUS Aortic Arch System - Zacks Investment Research
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday - Sahm
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Artivion, Inc. (AORT) Stock forecasts - Yahoo Finance UK
FDA Greenlights Artivion's (AORT) Nexus Aortic Arch System - GuruFocus
Stocks making big moves yesterday: Levi's, Strategy, Vishay Precision, Celsius, and Artivion - Yahoo Finance
Artivion (AORT) Receives "Buy" Rating Reiteration from Needham | - GuruFocus
Needham reiterates Artivion stock rating on FDA approval By Investing.com - Investing.com South Africa
Needham reiterates Artivion stock rating on FDA approval - Investing.com
Artivion stock gets FDA approval for NEXUS stent graft system By Investing.com - Investing.com Australia
Artivion stock gets FDA approval for NEXUS stent graft system - Investing.com
FDA approves Artivion’s NEXUS system for aortic arch disease - Investing.com
Needham Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $58 - Moomoo
FDA approves Artivion’s NEXUS system for aortic arch disease By Investing.com - Investing.com South Africa
Artivion Says FDA Approves NEXUS Aortic Arch System, Secures Option to Acquire Endospan - marketscreener.com
Artivion announces U.S. FDA approval of the Nexus® aortic arch system - marketscreener.com
Artivion Announces U.S. FDA Approval Of The Nexus® Aortic Arch System - TradingView — Track All Markets
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System - ChartMill
Analyst Downgrade: What is the long term forecast for Artivion Inc stockWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Why Artivion (AORT) Stock Is Down Today - Yahoo Finance
Artivion Inc (AORT) Trading Down 3.24% on Apr 6 - GuruFocus
SG Americas Securities LLC Raises Stake in Artivion, Inc. $AORT - MarketBeat
Artivion, Inc. (AORT) stock price, news, quote and history - Yahoo Finance UK
Artivion, Inc. (AORT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Holloway Jean F, Artivion SVP, sells $83k in shares - Investing.com
Artivion Inc Com (AORT) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Artivion (NYSE:AORT) Shares Gap DownShould You Sell? - MarketBeat
Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & SuppliesCardiology, Neurology, Vascular Stocks - Yahoo Finance
JPMorgan Chase & Co. Has $5.17 Million Position in Artivion, Inc. $AORT - MarketBeat
Is It Too Late To Consider Artivion (AORT) After A 161.6% Three Year Rally? - Yahoo Finance
How The Artivion (AORT) Narrative Is Shifting After A Trimmed Target And Steady Fair Value - Yahoo Finance
Artivion, Inc. (AORT) Stock Forecasts - Yahoo Finance
EDGAR Filing Documents for 0001999371-26-007510 - SEC.gov
Artivion (AORT) details 2026 virtual meeting, director slate and Say on Pay - Stock Titan
[ARS] ARTIVION, INC. SEC Filing - Stock Titan
Artivion (NYSE:AORT) Shares Down 6.6%What's Next? - MarketBeat
Take Profit: Will Artivion Inc stock go up in YEAR2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Artivion, Inc. (CYL.F) stock price, news, quote and history - Yahoo Finance UK
Artivion Inc Stock (AORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):